Cancer and Leukemia Group B/Southwest Oncology Group Trial 80405: A Phase III Trial of Chemotherapy and Biologics for Patients with Untreated Advanced Colorectal Adenocarcinoma-Reference-Cited by-同舟云学术

Cancer and Leukemia Group B/Southwest Oncology Group Trial 80405: A Phase III Trial of Chemotherapy and Biologics for Patients with Untreated Advanced Colorectal Adenocarcinoma

Published:2005-11 Issue:4 Volume:5 Page:292-294
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Venook Alan P.,Blanke Charles D.,Niedzwiecki Donna,Lenz Heinz-Josef,Taylor John R.,Hollis Donna R.,Sutherland Susan,Goldberg Richard M.

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference10 articles.

1. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment;Grothey;J Clin Oncol,2004

2. Colorectal metastases confined to the liver: a unique opportunity?;Venook;Semin Oncol,2003

3. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

4. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale;Colucci;J Clin Oncol,2005

5. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;Andre;N Engl J Med,2004

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer;Journal of Advanced Research;2024-08

2. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer;Oncogene;2021-08-12

3. Liver Metastases;Abeloff's Clinical Oncology;2020

4. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study;Annals of Oncology;2018-03

5. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer;PLOS ONE;2017-08-11